BioSET seals $11m financing:
This article was originally published in Clinica
Executive Summary
BioSurface Engineering Technologies (BioSET), a developer of synthetic peptide growth factors for advanced tissue repair, has completed an $11m financing round. The company intends to use the funds to commence human clinical trials of its synthetic B2A growth factor product for spine fusion, and to advance pre-clinical development of further products. The financing was led by PTV Sciences and included the participation of new investors Westfield Capital and Heron Capital, and existing shareholders Vertical Group, EDF Ventures MB Ventures and New Markets Growth Fund. According to industry analysts, the US market for growth factor-based bone graft products was more than $650m in 2006, with an annual growth rate of 33%. The estimated bone substitute materials market in 2006 is approximately $1.4bn.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.